Impact of Empiric Carbapenem Beta-Lactam (CBL) Versus Non-Carbapenem Beta-Lactam (N-CBL) Treatment on Mortality and Microbiological Response Rates for Third-Generation Cephalosporin-Resistant (3GCR) Enterobacteriaceae Bloodstream Infections (BSI) | Zendy

Melissa Kirejczyk | Zendy; Srijana Jonchhe | Zendy; Stephanie E. Giancola | Zendy; Michael Hogan | Zendy; Sunwoo Ahn | Zendy; Monica V. Mahoney | Zendy; Graham M. Snyder | Zendy; Kirthana Beaulac | Zendy; Elizabeth B. Hirsch | Zendy

Open Access

Impact of Empiric Carbapenem Beta-Lactam (CBL) Versus Non-Carbapenem Beta-Lactam (N-CBL) Treatment on Mortality and Microbiological Response Rates for Third-Generation Cephalosporin-Resistant (3GCR) Enterobacteriaceae Bloodstream Infections (BSI)

Author(s) -

Melissa Kirejczyk,

Srijana Jonchhe,

Stephanie E. Giancola,

Michael Hogan,

Sunwoo Ahn,

Monica V. Mahoney,

Graham M. Snyder,

Kirthana Beaulac,

Elizabeth B. Hirsch

Publication year - 2016

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofw172.755

Subject(s) - cephalosporin , carbapenem , medicine , beta lactam , microbiology and biotechnology , lactam , enterobacteriaceae , bloodstream infection , carbapenem resistant enterobacteriaceae , beta lactamase , antibiotics , biology , escherichia coli , chemistry , gene , biochemistry , stereochemistry

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research